Technology | June 11, 2012

Best Cyclotron Unveils Five New Systems at SNM

New type of cyclotron can produce technetium-99m without the need for a nuclear reactor

June 11, 2012 — Best Cyclotron Systems is unveiling five new cyclotrons for isotope research and production at the Society of Nuclear Medicine (SNM) 2012 Annual Meeting on June 9-12 in Miami Beach, Fla.

Drawing on more than 50 years in medical equipment manufacturing expertise, the new product line of cyclotrons offers a cost-effective alternative to both short- and long-lived medical isotopes. A cyclotron uses a combination of magnets and radio frequency electric fields to accelerate ions to velocities high enough to create isotopes. BTL has a unique cost-effective technology to manufacture five types of cyclotrons: 14 MeV (B14), 25 MeV (B25), 25 MeV upgradable to 35 MeV (B25u), 35 MeV (B35) and 70 MeV (B70). These cyclotrons will focus on isotopes used in positron emission tomography (PET), single photon emission computed tomography (SPECT) and therapy by virtue of their respective energies.

Best Cyclotron Systems has incorporated modern technology into their five cyclotron designs and configure the systems exactly to the end-user needs, whether it is for single-hospital application, regional pharmacies or national facilities. The high current features of the cyclotrons (400-1,000 micro-amperes) together with the low radio-activation of the cyclotron systems allow a broad range of commercial radioisotope production processes even on the B14p cyclotron.


Direct Production of Tc99m 

This unique processing system, available from TeamBest, can be used with Best Theratronics’ B14 and B25 cyclotrons or other suppliers’ cyclotrons to produce enough technetium-99m (Tc-99m) to adequately meet the clinical needs of large urban centers. The long-term supply of Tc99m for nuclear medicine is no longer dependent on reactor-supplied material. The TeamBest system can use the existing, yet small, cyclotron infrastructure or with new cyclotron sites, all for a much lower incremental cost compared to alternative systems and other isotope production technologies.

There have been shortages of Tc-99m in the past due to the reliance on a small number of isotope production reactors located outside the United States, namely the Chalk River facility in Ontario, Canada. Even short shut downs for maintenance have caused severe radio pharmaceutical shortages. 

Tc-99m is a primary SPECT imaging agent for several types of imaging exams, and the key imaging agent for SPECT myocardial perfusion imaging. 

For more information: www.teambest.com

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init